Barlow-Hall in vitro Evolution Protocol by Barry G. Hall & Miriam Barlow
1 
Barlow-Hall in vitro Evolution Protocol 
 
 
Barry G. Hall*  and Miriam Barlow† 
 
*Bellingham Research Institute, Bellingham, WA  Email drbh@mail.rochester.edu 
† University of California at Merced, 5200 N. Lake Rd, Merced, CA.   Email mbarlow@ucmerced.edu 
 
 
Background ............................................................................ 2 
Reagents ................................................................................. 2 
Equipment .............................................................................. 3 
Software ................................................................................. 3 
Procedure 
1 Amplify the target gene ............................................ 3 
2 Clone the target gene into pACSE vector.................. 3 
3. Mutate the target gene ............................................. 3 
4. Prepare digested vector............................................ 4 
5. Digest mutagenized amplicon pool .......................... 4 
6. Clone the mutagenized amplicon ............................. 5 
7. Electroporation........................................................ 5 
8. Determine library size & expand population............ 5 
9. The following day ................................................... 5 
10. Selection................................................................ 6 
11. Clonal Displacement.............................................. 6 
12. InVitroSimII simulator program ............................ 7 
 
Acknowledgments .............................................................. 7 
Literature Cited .............................................................. 7 
Appendix I    Electroporation ...................................... 9 
Appendix II   pACSE plasmid vectors ......................... 11 
Appendix III Recipes .................................................. 13 
Appendix IV Boiling DNA preps................................ 13 
 
2 
Background 
 Although the Barlow-Hall method1, like DNA shuffling2 and classical error-prone PCR3, can be 
used as a tool for protein engineering, its primary application is for predicting protein evolution in nature.  
Libraries generated by error-prone PCR amplification of a target gene by the Mutazyme II polymerase are 
subjected to selection or screening for expression of mutant proteins that have increased activities or 
expanded substrate ranges. The primary difference between the B-H method and other in vitro evolution 
methods is that the mutation frequency is precisely controlled.  Because the mutation frequency can be set 
by the investigator it is possible to quantify the proportion of the possible single-mutant and double-
mutant targets that are present in a library.  In nature mutations arise one, and very rarely two, at a time, 
and the resulting alleles must be fixed into population by selection for an improved protein function.  
From the proportion of possible single and double mutants present in a library, if no improved proteins 
are obtained the probability that a successful mutant could arise in nature but has been missed by chance 
alone can be estimated. The method closely mimics natural evolution1 and has been used to predict the 
natural evolution of several antibiotic resistance genes4-8.  The method also predicts which amino acid 
substitutions will cause the new phenotype and the order in which they will appear in nature, and at least 
two such predictions have been confirmed, e.g. TEM-1324,9 and CTX-M-35 (GenBank AB176534 )8 .  
The method has also been able to predict the absence of evolutionary potential, e.g. that the IMP-1 
metallo-β-lactamase does not have the potential to evolve increased activity toward imipenem7. 
 The Barlow-Hall method is the subject of US Patent Number: US 6,720,142 B1.  Commercial 
application of the Barlow-Hall method is subject to a license from The University of Rochester Office of 
Technology Transfer, Rochester, NY. 
 
Materials 
Reagents 
FailSafe™ PCR kit (Epicentre) OR Phusion High-Fidelity Taq polymerase (NEB #F-530S) {highly 
accurate and efficient amplification} 
Restriction enzymes NcoI (NEB) and BspHI (NEB) 
T4 ligase 
T4 ligase buffer 
GeneMorph™ II Random Mutagenesis Kit (Stratagene) consisting of: 
Mutazyme™ II polymerase. 
40 mM dNTP mix (200µM each final) 
10x Mutazyme II reaction buffer  
Oligonucleotide F1: 5’-TCATCCGGCTCGTATAATGTGTGGA 3' 
Oligonucleotide R1: 5’-ACTCTCTTCCGGGCGCTATCAT-3’ 
Calf Alkaline Phosphatase (CIP) (NEB) 
SOC broth {Appendix III} 
L-broth {Appendix III} 
plasmid pACSE2 (NcoI cloning site) {see Appendix II} 
plasmid pACSE3 (BspHI cloning site, must be prepared from dam- host.)  {See Appendix II} 
Note: plasmids pACSE2 and pACSE3 my be obtained upon request to M. Barlow. 
Electrocompetent E. coli strain DH-5α with an electroporation efficiency of at least 1 x 1010 per µg.  
(NEB 5-alpha Electrocompetent E. coli cat. # C2989K) or the same strain prepared as described in 
Appendix I. 
 
Equipment 
Thermal cycler programmed with the desired amplification protocol 
DNA fluorometer or NanoDrop to measure DNA concentrations accurately 
QIAquick PCR purification kit (Qiagen) 
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OR QIAquick gel purification kit (Qiagen) 
Electroporator and electroporation cuvettes 1 mm gap 
 
Software 
InVitroSimII, a Perl program 
 
 
Procedure 
1  Amplify the target gene 
Amplify the target gene using a high-fidelity systems such as the FailSafe system or Phusion 
High-Fidelity Taq polymerase according to manufacturer's instructions. A 50µl reaction should 
provide sufficient amplicon product. 
The forward primer should include the ATG initiation codon within either an NcoI or a BspHI 
restriction site and there should be at least 7 bases 5' to that site.  The reverse primer should 
include a restriction site for a second enzyme that does not cut within the target gene but does cut 
within thepACSE2/pACSE3 cloning cartridge.  If possible the second enzyme should work in the 
same buffer as NcoI or BspHI.  The use of two enzymes ensures directional cloning so that the 
target gene will be in the correct orientation in the plasmid.  See Appendix II for cloning cartridge 
details. Purify the amplicon with a QIAquick PCR purification column OR run the PCR product 
on a gel, cut out the band corresponding to the expected size and purify with a QIAquick gel 
purification column and determine the DNA concentration with a DNA fluorometer or NanoDrop.  
 
2 Clone the amplicon into pACSE2 (NcoI site) or pACSE3 (BspHI site). 
Digest about 1 µg of plasmid and about 1 µg of amplicon with the appropriate restriction enzyme.   
Purify the digests with QIAquick PCR columns and determine the DNA concentration with a 
DNA fluorometer or NanoDrop. 
Combine 300 ng digested plasmid with 89 fmol digested amplicon, 4 µl T4 ligase buffer, 2 µlT4 
ligase and sterile water to a total volume of 20 µl and allow to ligate overnight at room 
temperature. 
Electroporate into E. coli strain DH5αE. {See Appendix I for electroporation procedure}. 
Plate serial dilutions of electroporated cells onto L-tetracycline agar {Appendix III} and incubate 
plates overnight at 37˚.  Grow 1 ml cultures from 20 well-isolated overnight in L-tetracycline.  
Make boiling DNA preps {Appendix IV} from each culture and run 10µl PCR reactions using 1µl 
of each boiling prep as template.  Run the PCR reaction products on a gel along with some 
digested plasmid and a size standard.  Choose two candidates that appear to have the correct insert, 
prepare plasmid DNA by any standard method, and sequence the insert.  Retain a candidate that 
has the correct sequence. 
See Troubleshooting Table 
 
3 Mutate the target gene. 
Decide the average number of mutations you want per molecule.  Two mutations per molecule is 
typical when you want to mimic natural evolution, about 14% of amplicons should have zero 
mutations, 27% 1 mutation, 27% two mutations, and 32% >2 mutations.   
First calculate the number of ng of target template that are required to produce the desired number 
of mutations per kb, then apply the equation 
! 
ng = e
m"12.6
"1.9 , where ng is the number of ng of target 
required and m is the desirerd number of mutations/kb.  Finally, calculate the amount of plasmid 
required for that amount of template. 
Example: 
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The target is 500 bp that have been cloned into pACSE2 and you want an average of two 
mutations per molecule.  Two mutations per 500 bp = 4 mutations per kb, so applying the 
above equation you require 92.4 ng target for a 50 µl reaction.  pACSE2 is 5201 bp, so the 
plasmid carrying the target is 5500 bp and the target constitutes 0.909 of the plasmid.  You 
will therefore require 1016 ng of the plasmid for the 50µl reaction. 
 
Set up the following PCR reaction to mutagenize the target gene: 
 
Plasmid volume as required by ng  
10X MutazymeII Buffer 5µl 
5 µM oligonucleotide F1 5µl 
5 µM oligonucleotide R1 5µl 
40 mM dNTP mix 1µl 
Mutazyme II enzyme 1µl 
H2O to give 50 µl final volume 
 
Run thermal cycler programsuggested by StrataGene for GeneMorph. 
(95C 2 min., [95C 30 sec., 58C 30 sec., 72C 1 min 10 sec]X30, 72C 10 min, hold at 4C).   
Determine the DNA concentration of the amplicon pool with a DNA fluorometer or NanoDrop.  
Important! The DNA concentration should be determined accurately.  This cannot be done 
by running serial dilutions on a gel. 
Purify the reaction with a QIAquick PCR column OR run the PCR product on a gel and cut out 
the band corresponding to the expected size  and purify using QIAquick gel purification columns 
(Qiagen).  
Quantify DNA once again. 
 
4  Prepare digested vector for library construction 
Digest 20 µg of pACSE2 or pACSE3 with the same enzymes used to clone the target gene plus 
CIP (calf alkaline phosphatase).  The CIP dephosphorylates the vector and prevents self-ligation 
of partially digested plasmid.  The yield is digested-dephosphorylated plasmid is typically 
sufficient for preparation of several parallel libraries. 
 
Set up the following reaction*: 
 
pACSE2 or pACSE3 20 µg 
Restriction enzyme 1 200 units** 
Restriction enzyme 2 200 units** 
10X Buffer 40 µl 
CIP 100 units 
H2O to give 400 µl final volume 
 
* This assumes that the two enzymes can be used with the same buffer and incubated at the same 
temperature.  If not, digest with the two enzymes sequentially and include the CIP in the second 
digest. 
**The combined volumes of the restriction enzymes and CIP should not exceed 40µl in order to 
keep the final glycerol concentration below 5%.  If necessary increase the volume of water and 
10x buffer. 
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Incubate the digest for two hours at 37˚, check digestion on an agarose gel and purify over two 
QIAquick columns, eluting each with 50µl of TE.  Typical yield is 10µg of digested vector.  
Determine the DNA concentration, typically about 100 ng/µl.  Digested  plasmid can be stored in 
TE at -20˚. 
 
5 Digest the mutagenized amplicon pool 
 Depending upon the size of the target gene, with an average of two mutations per amplicon 
and the effective library size of 107, the fraction of all possible single and double mutants in a 
single library ranges from about 75% for a target of about 500 bp to about 30% for a target of 
1400 bp.  To have 95% confidence of screening all possible single and double mutants thus 
requires screening three libraries in the former case and nine libraries in the latter case.  Multiple 
independent libraries can be prepared from the same amplicon pool because each ligation consists 
of about 1011 amplicons of which only about 107 are sampled in a good library.  Each library is 
thus effectively an independent sample of the pool of alleles. 
For each library that you require, digest 550 fmol of amplicon with the two appropriate 
restriction enzymes. When the size of the amplicon is expressed in base pairs calculate the number 
of nanograms required according to ng = (fmol * size)/1543.  For a 1000 bp amplicon this is 357 
ng for each library.   Purify on a QIAquick column and elute in 50µl. Determine the DNA 
concentration. 
Run an aliquot of the digest on a gel along with appropriate size standards and estimate the 
fraction of the digest that is amplicon.  Depending upon the amount of target template used in the 
mutagenesis reaction, a significant fraction of the digest may be plasmid (5 kb band).  In step 6 
correct the amount of digested amplicon by increasing the amount of DNA as necessary to account 
for the plasmid DNA. 
 
6 Clone the mutagenized amplicons 
In separate tubes, for each ligation combine, in order: 
600 ng of digested dephosphorylated plasmid 
534 fmol digested amplicon 
Incubate at 56oC for 10 minutes and cool to room temperature 
Add remaining: 
8 µl 5x T4 DNA ligase buffer 
H2O to give a total of 38µl 
2 µl T4ligase 
* If vector and/or amplicon concentrations do not permit doing the reaction in 40µl volume, 
increase the amounts of T4 ligase and ligase buffer accordingly. 
 
Incubate overnight at room temperature (16 to 24 oC) and EtOH precipitate at follows: 
 Combine 20 µl ligation mix, 1 µl tRNA [1 µg/µl Yeast/AMBION], 55 µl cold 100% 
EtOH.  Incubate at -20 oC for at least 15 minutes.  Centrifuge 15 min., 15K rpm, at 4 oC. 
Remove supernatant, wash the pellet with 70% EtOH, spin again, remove supernatant, air 
dry the pellet.  Resuspend the pellet  in 5 µl sterile water. 
 
Purify over a Qiagen min-elute column and elute each in 10µl TE.   
 
 
7 Electroporation 
Work in a cold room using a cold electroporator and cold electroporation cuvettes.  For each 
electroporation have a tube containing 1.0 ml SOC in a dry bath (or water bath) at 37˚ on the 
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bench in the cold room.  Also have a dry bath at 37˚ into which the electroporation cuvettes can be 
placed immediately after electroporation. 
 
Thaw one 4x aliquot of electrocompetent cells on ice.  As soon as it is thawed add the purified 
ligation from step 5.  Mix briefly (but gently) and transfer to four electroporation cuvettes. 
 
Electroporate as described in Appendix I except that the four electorporations are combined with 4 
ml SOC in a single tube for expression. 
Allow the tet gene to express for 1.5 hour. 
 
8 Determine the library size and expand the transformed population 
Add the entire undiluted transformation to 500 ml of L-tetracycline in a tightly sealed 500 ml flask 
and allow to stand overnight without aeration at 37˚. This expands the library. Plate serial dilutions 
from this culture in triplicate onto L-tet agar to determine the number of transformants. Incubate 
overnight at 37˚. 
 
 
9  The following day: 
Determine the absorbance at 600 nm of the expanded library. Plate serial dilutions of the expanded 
library onto L-tet to determine the population size. For DH5α, when A600 =1, there are 1.9 x 108 
cfus/ml . 
 
Count the colonies from yesterday and calculate the total library size. 
Freeze aliquots that contain at least 20 x the size of the library at -80˚ for future use. 
Pick at least 20 well-isolated colonies from suitable dilution plates and make boiling DNA preps 
from each (see Appendix IV) 
Use the boiling DNA preps as templates in PCR reactions using primers F1 and R1. 
Run the PCR reactions on a gel.  From the proportion of insert bearing transformants calculate the 
effective library size. 
 
To be useful the effective library size must be at least 2 x 106, but we typically get 1 x 107 or 
slightly better. 
 
10 Selection 
The selection routine will depend upon the new function that is being evolved, but the routine for 
selecting for new antibiotic resistance can be suitably modified. 
1. Dilute a frozen aliquot of a library into 50 ml of L-tet containing 1mM IPTG and grow to an 
A600 of about 0.2.  The IPTG induces expression of the cloned target gene. 
2. We carry out selection for drug resistance in 50 ml cultures in 100 ml bottles, so we dilute the 
library in L-broth so that the number of cells per 50 ml is about 10x thelargest library size. (If 
multiple libraries are being selected for the same function, use the same concentration of cells for 
the selections even though thelibrary sizes are different in order to eliminate inoculum size effects.  
This ensures that each culture contains at least one copy of each mutant allele in the library.  Since 
we want to select at a series of different drug concentrations we typically prepare about 500 ml of 
the diluted culture.  A good library will have an effective size of about 107, so we will typically 
have about 108 cells in 50 ml, or about 2 x 106 per ml.  That population density means that it is 
easy to distinguish growth from non-growth the following day. 
3. We distribute 100 ml of the diluted library to the first bottle and 50 ml to each remaining bottle.  
We then add Drug-X to the first bottle to give the highest concentration to be tested.  We mix, then 
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transfer 50 ml from that bottle to the next bottle, etc. to achieve a set of two-fold dilutions of the 
drug.  From the final bottle we discard 50 ml to ensure that all bottle have the same volume.  
Alternatively, bacteria can be added to the bottles after the serial dilutions of Drug-X are made.  
This reduces the possibility of cross contamination between cultures. 
4. The bottles are tightly capped then allowed to stand overnight at 37˚.  Tightly capping the 
bottles limits oxygen availability so that the cultures do not become over saturated. We use square 
bottles rather than flasks because this minimizes the surface area.  These standing overnight 
cultures limit out at about 109 /ml. 
 The culture which grew in the highest concentration of tested drug is transferred (500 µl 
into 10 ml) into fresh broth with the same concentration of antibiotic and 2X higher. Bacteria from 
the tube where growth is clearly visible are harvested and plasmid DNA is isolated for subsequent 
electroporation into DH5αE. The next day 10 single clones are picked for DISC diffusion MIC 
test. 
5.  Analyze the phenotypes of the tested clones and send for sequencing at least 1 representative 
clone for each distinct phenotype. 
 
 
 
11 Clonal displacement 
 The selection described above makes it very likely that after selection the population will 
consist of a single allele that represents the fittest mutant in the library.  Although the initial 
population might have been 2 x 106 cells/ml, and the final population 109, the vast majority of that 
initial population will not have grown at all during selection because most mutants will be either 
non-functional or no better than the initial unmutagenized allele.  Suppose that of 107 mutant 
alleles there were 10 that were fitter than the original allele, and each of those was present in 10 
copies.  If they were equally fit each would have generated 107 descendants resulting from 23 
doublings.  That is plenty of time for any fitness differences to have taken effect, and it is likely 
that the fittest mutant will have outgrown the others so that it is >95% of the population - hence 
the term "clonal displacement".  Our experience with antibiotic resistance confirms this 
expectation.  We typically test 20 colonies from the population that grew at the highest drug 
concentration.  Using antibiotic diffusion discs which give a continuous measurement that can 
discern a finer scale of differences than 2x dilutions can, we very rarely see more than one 
phenotype in a population after selection. 
 If it is important to detect as many improved variants as possible one could dilute the 
culture so that there were on average 0.2 copies of each mutant allele (instead of 10) and do 25 
parallel selections.  That would improve the chances of detecting additional successful, but not 
equally fit, alleles. 
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12 InVitroSimII simulator program 
When in vitro evolution results in an improved gene - a product with a new substrate specificity or 
with increased activity - you can demonstrate that the gene has the potential to evolve that new 
activity in nature.  But what happens when in vitro evolution fails to produce an improved gene?  
Can you conclude that the gene lacks the potential for that activity and will not evolve that activity 
in nature?  In the case of antibiotic resistance it may be very important to know whether the 
potential for resistance to a new drug really does not exist.  Can negative evidence permit drawing 
such a strong inference?  After all, the in vitro experiment may not have included the necessary 
mutations just by chance alone. 
 If, as a practical matter, we accept that unless an improved phenotype can arise as the 
result of one or two mutations it will not arise in nature, then we can calculate the fraction of all 
possible single and double mutants are likely to be present in a library of a given size.  The 
calculation is not straight forward because it depends upon the starting sequence of the gene under 
selection. 
 Actually, we are not interested in all possible single and double mutations, we are 
interested only in those mutations that change the protein sequence: single mutations that change 
one amino acid, double mutations in the same codon that change one amino acid, and double 
mutations in two codons that change two amino acids. 
 The program InVitroSimII simulates a random mutation process and keeps track of all of 
the amino acid replacement molecules.  The user provides the starting gene sequence, the average 
number of mutations per molecule, and the effective library size.  The program reports the fraction 
of single and double mutants (that change the protein sequence) that occurred. Of course, the 
longer the gene and the smaller the library, the smaller will be the fraction of possible mutants in 
the library.  However, if you know that you screened four libraries each of which included 85% of 
all the possible single and double mutants, you know that the probability that you missed one 
possible mutant by chance is 5 x 10-4.  If you failed to detect an improved phenotype among those 
four libraries then you can be 99.95% confident that an improved phenotype will not evolve in 
nature. 
 InVitroSimII compiled  for Macintosh OSX and for Windows, and the source code that can 
be compiled for Unix/Linux systems, can be downloaded at no charge from 
http://homepage.mac.com/barryghall/Software.html 
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Appendix I Electroporation 
In order to achieve large libraries, i.e. close to 107, it is necessary to use extremely electrocompetent cell 
preparations.  This protocol describes how to prepare them.  
 
The following materials must be in the cold room the day before preparing the cells 
Two sterile 250 ml centrifuge bottles 
Rack of tips for 1 ml Pipetteman 
Rack of tips for 200 µl Pipetteman 
Sterile 10 ml pipettes 
2 100 ml bottles of sterile water 
A bottle of sterile 10% (v/v) glycerol 
A bottle of sterile 20% (v/v) glycerol 
Some sterile 50 ml centrifuge tubes 
 
In a -80˚ freezer the day before the preparation 
A rack of a sufficient number of closed 0.5 ml microfuge tubes.  These should be thick wall tubes, not 
tubes for PCR.  The rack must be a solid plastic or metal rack of the sort that the tubes fit snuggly into 
each hole that is tapered.  It is essential that the walls of the tube are in full contact with the rack, not with 
air.  The rack acts as a heat sink that keeps the tubes close to -80˚ while the cells are being dispensed into 
the tubes and allows the cells to freeze instantly. 
 
 
Cell preparation 
NOTE!!!  The faster the prep is done the greater will be the Electroporation efficiency, so move quickly, 
without hesitation, but carefully.  Be very familiar with the entire procedure before you begin. 
 
Use as light a rotor as is available for the centrifuge steps.  The lighter the rotor the more quickly it will 
stop and the better will be the prep.  This matters. 
 
1. The afternoon before the preparation inoculate an overnight culture in 10 ml YENB (see Appendix 
III) and grow it at 37˚with good aeration.  The day of the preparation add 5 ml of the overnight culture 
to a 2L flask containing 500 ml of YENB.  Shake at 37˚ until A600 is exactly 0.6 (never over 0.6), this 
will typically take 120 - 150 minutes.  Check A600 at no more than 10 minute intervals after A600 
reaches 0.3 and more frequently as A600 gets over 0.5. 
2. Chill the flask on ice for about 5 minutes then spin down in sterile 250 ml centrifuge bottles at 1200 x 
g (3500 RPM in a Sorval SLA rotor) at 4˚ for 5 minutes.  When working with large volumes spin down 
250 ml, discard the supe, add another 250 ml and spin again.  Do not exceed two spins.  Do not 
increase volume of washes in following steps.  From this point on keep the cells on ice at all times 
when carrying between the centrifuge and the cold room.  Place on ice instantly upon removal from 
the centrifuge.  Do all the work in a cold room. 
3. Pour off supe and hold bottle upside down a few seconds to allow all supe to drain off.  Immediately 
put the bottle back on ice.  Resuspend one pellet by adding 10-20 ml of cold sterile water and swirling 
until entire pellet is suspended.  You can pipette the suspension gently up and down to obtain a 
homogeneous suspension.  Do not vortex!  Be gentle!  Add the remainder of 100 ml bottle of cold 
sterile water.  Use about 20 ml of that suspension to suspend the cells in the other bottle and combine 
the pellets.  Centrifuge again  at 1200 x g (3500 RPM in a Sorval SLA rotor) at 4˚ for 5 minutes. 
4. Repeat step 3 
5. Resuspend cells in 10 ml cold 10% glycerol by swirling and centrifuge again  at 1200 x g (3500 RPM 
in a Sorval SLA rotor) at 4˚ for 5 minutes..  While the rotor is slowing down bring the rack of -80˚ 
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microfuge tubes into the cold room.  Do not put the rack on ice - the ice will warm up the tubes faster 
than will the air. 
6. Resuspend pellet in 1.0 ml of cold 20% glycerol by pipetting up and down with a 1.0 ml pipetteman. 
7. Distribute 40 µl aliquots of cells to the sterile -80˚ 0.5 ml microfuge tubes.  This works best by using 
an electronic pipetteman that allows you to take up 1.0 ml and to repeatedly dispense 40 µl aliquots.  
Immediately carry the rack to the -80˚ freezer.  Do not put the rack on ice - the ice will warm up the 
tubes faster than will the air. 
8. Label a small storage box with the strain name, date, some sort of code to identify this specific 
preparation, and a reference to the page in your notebook where you recorded the prep.  Store the box 
in the -80˚ freezer 
9. After and hour or so quickly transfer the tubes from the rack into the labeled box 
 
Electroporate one sample of the prep with a standard amount of a good standard supercoiled plasmid to 
determine the Electroporation efficiency.  We use a commercial preparation of pUC18 or pUC19 that has 
been diluted to exactly 10 pg/µl and electroporate with exactly 1 µl as described below.  After expression 
(see Electroporation below) plate 10x, 100x and 1000x dilutions onto L-ampicillin.  
 
 
Electroporation - Do steps 1-5 in the cold room 
Keep Electroporation cuvettes in the cold room.  Use cuvettes with 1.0 mm gap. 
 
1. Thaw tubes of electrocompetent cells on ice in the cold room for a very few minutes.  Proceed as soon 
as the tubes are thawed 
2. Add 1 to 5 µl of DNA inTE buffer or water to the cells.  Hold on ice 0.5 to 1.0 minutes. 
3. Set the Gene Pulser (BioRad) electroporator to 25 µF and 1.6 kV, and the Pulse Controller at 200 Ω.  
(If using a different machine set as specified by the manufacturer of E. coli) 
4. Using a cold pipetteman tip, transfer the cell-DNA mixture to a cold cuvette and pulsed. 
5. Immediately add 1.0 ml of SOC {see Appendix III} at 30˚ to the cuvette and suspend the cells by 
gently shaking up and down.  Immediately put the cuvette into a 37˚ dry bath or other device to keep 
the cells at 37˚ 
6. After all samples have been electroporated transfer the cells to a sterile 18 x 150 mm capped tube that 
contains 1.0 ml SOC and aerate at 37˚ for 1.5 hr to allow the antibiotic resistance gene on the plasmid 
to express.  {If it is necessary to express at 30˚ allow two hours} 
7. Plate onto selective medium, resuspending in buffer prior to plating if necessary; e.g. when selecting 
for growth on a particular carbon source or growth in the absence of a particular nutrient.
12 
Appendix II pACSE plasmid vectors 
 
pACSE2 used for cloning into the NcoI site 
pACSE2 (5201 bp) is derived from pACYC184 and carries the p15A origin of replication that results in a 
copy number of 5-10 per cell.  It carries a multiple cloning site (MCS) cartridge (bp 534-860), a 
tetracycline resistance gene, and the lac repressor gene lacIq.  Genes cloned into the MCS are expressed 
from the powerful pTAC promoter (bp 347-533) under control of the lacIq repressor.  The unique NcoI 
site is at the initiation codon for expression from the pTAC promoter. 
 
 
The unique sites within the MCS are: 
Alphabetical order Sequence order 
HpaI 727 NcoI 534 
KpnI 719 MfeI 633 
MfeI 633 KpnI 719 
NcoI 534 HpaI 727 
NotI 783 StuI 766 
NsiI 775 NsiI 775 
PstI 794 NotI 783 
SacI 844 PstI 794 
StuI 766 XhoI 843 
XhoI 843 SacI 844 
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pACSE3 used for cloning into the BspHI site 
pACSE3 (5087 bp) was created from pACSE2 by elimination of a BspHI site within the tet gene, 
converting the NcoI site to a BspHI site, digesting with BspHI and self-ligating to remove the 114  bp 
534-648 fragment within the cloning cartridge.   The unique BspHI site is at the initiation codon for 
expression from the pTAC promoter. 
 
The BspHI site is methylated by the dam methylase and when methylated is not cut by BspHI.  pACSE3 
must be grown in a dam- strain such as GM19 in order for it to be digested by BspHI. 
 
 
The unique sites within the MCS are: 
Alphabetical order Sequence order 
BspHI 534 BspHI 534 
HpaI 613 KpnI 605 
KpnI 605 HpaI 613 
NotI 669 StuI 652 
NsiI 663 NsiI 663 
PstI 680 NotI 669 
SacI 730 PstI 680 
StuI 652 XhoI 729 
XhoI 729 SacI 730 
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Appendix III Recipes 
 
L-broth 
Per liter: 
10 g Bacto tryptone (Difco) 
5 g Bacto yeast extract (Difco) 
10 g NaCl 
10 g glucose 
 
 
YENB 
7.5 g Bacto Yeast extract (Difco) + 8 g Bacto Nutrient Broth (Difco) per liter 
 
 
SOC 
2% (w/v) Bacto tryptone (Difco) 
0.5% (w/v) Bacto yeast extract (Difco) 
10 mM NaCl 
2.5 mM KCl 
10 mM MgSo4 
20 mM glucose 
 
 
Appendix IV Boiling DNA plasmid preps 
 
Method 1 
1. Using a sterile toothpick suspend a medium to large colony in 50 µl water in a thick-wall 0.5 ml 
microfuge tube.  Be sure not to pick up any agar as agar will inhibit downstream reactions such as 
PCR.  Close tube cap tightly 
2. Heat at 100˚ in a thermocycler for 5 minutes. 
3. Spin one minute in microfuge 
4. Use 1-5 µl of supe as template in PCR reaction 
 
Method 2 
1. Grow a 1 ml overnight culture in broth 
2. Spin down 50 µl of overnight culture 
3. Resuspend in 50 µl water or TE 
4. Heat at 100˚ in a thermocycler for 5 minutes. 
5. Spin one minute in microfuge 
6. Use 1-5 µl of supe as template in PCR reaction 
  
 
